Full Breakdown
Potential Shift in U.S. Cannabis Policy: Executive Order on Rescheduling
12/16/2025, 1:34:08 AM
Overview of the Proposed Change
President Donald Trump is anticipated to sign an executive order that would reclassify marijuana from Schedule I to Schedule III under federal law. This reclassification represents a significant shift in U.S. drug policy, acknowledging cannabis's lower potential for abuse compared to its previous classification. While this change would not legalize marijuana nationwide, it could facilitate expanded medical research, alter federal prosecutions, and improve banking access for cannabis businesses.
Key Figures and Stakeholders
The discussions surrounding this potential policy change involve several key figures. Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz have expressed support for federal cannabis reforms. In contrast, House Speaker Mike Johnson has voiced opposition to the proposed changes. Senator Tom Cotton of Arkansas, a notable critic of legalization, has indicated a cautious stance, emphasizing concerns over the increased potency of modern cannabis products and their potential risks, particularly for youth.
Market Reactions and Speculation
The speculation regarding the executive order has led to significant market activity, particularly for Canadian cannabis producer Canopy Growth. Following rumors of the impending policy change, Canopy Growth's stock surged by approximately 52%, reflecting investor optimism about a more favorable regulatory environment. Other companies in the sector, such as Tilray Brands and Aurora Cannabis, also experienced stock price increases, indicating a broader market response to the anticipated regulatory shift.
Implications of Rescheduling
If enacted, the reclassification to Schedule III would alleviate the burdens imposed by Section 280E of the Internal Revenue Code, which currently prevents cannabis businesses from deducting standard operating expenses. This change could enhance the financial viability of cannabis companies and foster growth within state-legal markets. Brian Vicente, a cannabis law expert, described the potential rescheduling as "monumental," highlighting its capacity to free cannabis businesses from crippling tax burdens.
Criticism and Opposition
Despite the potential benefits, there are dissenting views regarding the reclassification. Senator Tom Cotton has articulated concerns about the implications of high-potency cannabis products, suggesting that while there may be public support for decriminalization, full legalization and commercialization are not widely favored in Arkansas. Critics argue that the increased potency of cannabis poses greater risks, particularly to children.
Conflicting Reports and Uncertainties
Reports regarding the timing of the executive order have varied, with some sources indicating a possible announcement as early as the coming Monday, while others suggest it may coincide with the presidential inauguration in January. This uncertainty has contributed to market volatility, as traders react to the fluctuating expectations surrounding the policy change.
Verbatim Quotes
- “Rescheduling releases cannabis businesses from the crippling tax burden they have been shackled with and allows these businesses to grow and prosper.” — Brian Vicente, Founding Partner at Vicente LLP
- “But I will say, marijuana today is nothing like it was in the 1960s.” — Senator Tom Cotton
The anticipated executive order could reshape the landscape of cannabis regulation in the United States, influencing both market dynamics and ongoing debates about legalization at the state level.
